All In Biotech

Drug Trial Radar · NCT01761968

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
First posted
Jan 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis following core protocols in chronic myeloproliferative neoplasms and/or patient-named compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments). Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 "Uso terapeutico di medicinale sottoposto a sperimentazione clinica" published on G.U. n. 173 of 28 July 2003, and the following amendments), they will be treated at the last tolerable dose of the combination. Assessment of safety and efficacy will be performed at each quarterly visit and each visit will also include laboratory tests and ECG examination. During the visits the clinical benefit will be assessed by Investigator according to the revised European LeukemiaNet response criteria (for PV and ET) and EUMNET response criteria (for MF). The dose of Givinostat will be modified for protocol specified toxicities. The treatment may continue up to Marketing Authorization of givinostat, currently planned in the next 5 years (note: only for Germany, this long-term study is initially limited up to 2 years of treatment). Patients may discontinue study treatment at any time and remain on study therapy as long as they derive clinical benefit. Safety will be monitored at each visit throughout the entire duration of the study. In case the approved label will not cover the whole study population, givinostat will be provided by the Sponsor to those patients not fulfilling the criteria for the approved label of the drug that are still deriving benefit from givinostat at the time of its commercial availability.

Conditions

  • Chronic Myeloproliferative Neoplasms

Interventions

  • givinostatDrug

    Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each. If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and efficacyTime frame: 3 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Charite Research Organization GmbH

    Berlin, Germany

  • Universitaetsklinikum Freiburg, Innere Medizin I - Haematologie und Onkologie

    Freiburg im Breisgau, Germany

  • Azienda Ospedaliera Universitaria Università degli Studi "Federico II", Naple

    Naples, Italy

  • Università "Campus Bio-Medico", Rome

    Rome, Italy

  • Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari

    Bari, BA, Italy

  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico di Bari

    Bari, BA, Italy

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, BG, Italy

  • Azienda Ospedaliero-Universitaria Careggi, Florence

    Florence, FI, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico UOS Oncoematologia anziano

    Milan, MI, Italy

  • Azienda Unità Sanitaria Locale - Presidio Ospedaliero "Spirito Santo", Pescara

    Pescara, PE, Italy

  • Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia

    Pavia, PV, Italy

  • Azienda Ospedaliera "Bianchi-Melacrino-Morelli"

    Reggio Calabria, RC, Italy

  • Ospedale San Bortolo, Vicenza

    Vicenza, VI, Italy

  • Belfast City Hospital

    Belfast, United Kingdom

  • Royal Cornwall Hospital

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.